Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17260435 | 1.00 | SLC6A2 (0.36) | SLC6A2MMP12MMP13 | |
| Hydrochloric Acid SCHEMBL18953979 | 0.98 | SLC6A2 (0.36) | SLC6A2MMP12MMP13 | |
| SCHEMBL2022509 | 0.80 | SLC6A2 (0.34) | SLC6A2MMP12MMP13 | |
| SCHEMBL12100629 | 0.80 | SLC6A2 (0.34) | SLC6A2MMP12MMP13 | |
| SCHEMBL28512295 | 0.77 | CYP4F2 (0.35) | SLC6A2MMP12MMP13 | |
| SCHEMBL17818233 | 0.77 | CYP4F2 (0.35) | SLC6A2MMP12MMP13 | |
| SCHEMBL16569687 | 0.76 | DGAT1 (0.39) | SLC6A2MMP12MMP13 | |
| SCHEMBL20025578 | 0.76 | SLC6A2 (0.33) | SLC6A2MMP12MMP13 | |
| SCHEMBL16569689 | 0.76 | DGAT1 (0.39) | SLC6A2MMP12MMP13 | |
| SCHEMBL17818301 | 0.75 | ACLY (0.37) | SLC6A2MMP12MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019038362-A1 | ANTIBACTERIAL PYRROLOIMIDAZOLONES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-02-28 | — | — | WO | disclosed |
| CN-106061977-B | 1, 2-dihydro-3H-pyrrolo [1,2-C ] imidazol-3-one derivatives and their use as antibacterial agents | 爱杜西亚药品有限公司 | 2018-10-26 | — | — | CN | disclosed |
| EP-3143007-B1 | ANTIBACTERIAL QUINAZOLINE-4(3H)-ONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-07-11 | — | — | EP | disclosed |
| EP-3334737-A1 | SUBSTITUTED 1,2-DIHYDRO-3H | Idorsia Pharmaceuticals Ltd (CH) | 2018-06-20 | — | — | EP | disclosed |
| CN-108137596-A | 1,2- dihydro -3H- pyrrolo-es [1,2-c] imidazoles -3- ketone antimicrobial compounds being substituted | 爱杜西亚药品有限公司 | 2018-06-08 | — | — | CN | disclosed |
| CN-107922433-A | Antibacterial Cyclic Pyrrolidin-2-one Derivatives | 爱杜西亚药品有限公司 | 2018-04-17 | — | — | CN | disclosed |
| US-9796686-B2 | Antibacterial quinazoline-4(3H)-one derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-10-24 | — | — | US | disclosed |
| US-20170081292-A1 | ANTIBACTERIAL QUINAZOLINE-4(3H)-ONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-03-23 | — | — | US | disclosed |
| EP-3143007-A1 | ANTIBACTERIAL QUINAZOLINE-4(3H)-ONE DERIVATIVES | Actelion Pharmaceuticals Ltd (CH) | 2017-03-22 | — | — | EP | disclosed |
| CN-106458931-A | Antibacterial quinazolin-4 (3H) -one derivatives | 埃科特莱茵药品有限公司 | 2017-02-22 | — | — | CN | disclosed |
| WO-2017025562-A1 | SUBSTITUTED 1,2-DIHYDRO-3H PYRROLO[1,2-c]IMIDAZOL-3 ONE ANTIBACTERIALS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-02-16 | — | — | WO | disclosed |
| EP-3114126-A1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | Actelion Pharmaceuticals Ltd (CH) | 2017-01-11 | — | — | EP | disclosed |
| CN-106061977-A | 1, 2-dihydro-3H-pyrrolo [1,2-C ] imidazol-3-one derivatives and their use as antibacterial agents | 埃科特莱茵药品有限公司 | 2016-10-26 | — | — | CN | disclosed |
| WO-2015173329-A1 | ANTIBACTERIAL QUINAZOLINE-4(3H)-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015132228-A1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081292-A1 | ANTIBACTERIAL QUINAZOLINE-4(3H)-ONE DERIVATIVES | MRPL21, PYM1, MDK | SLC6A2 3724/4885MMP12 2980/4885MMP13 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.